Physician profile
William M Edwards
NPI 1952409997
$1,290,013.16
in general payments reported to CMS, 2019-2025
17 companies · $450K in 2025
The $450K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2021: $102K · 2022: $222K · 2023: $311K · 2024: $204K · 2025: $450K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $654K · Royalty Or License: $311K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $654,120.88 |
| Royalty Or License | $310,711.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| American Rheumatology Network, LLC | $1,289,264.23 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $127.33 | 2019 | |
| Ucb, INC. | $117.76 | 2019 | |
| Abbvie INC. | $83.01 | 2019 | |
| Merck Sharp & Dohme LLC | $76.67 | 2019 | |
| Gilead Sciences, INC. | $66.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $55.53 | 2019 | |
| Lilly USA, LLC | $42.43 | 2019 | |
| Genentech USA, INC. | $37.06 | 2019 | |
| Pfizer INC. | $36.61 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.33 | 2019 | |
| Glaxosmithkline, LLC. | $18.77 | 2019 | |
| Medexus Pharma, INC. | $11.92 | 2019 | |
| Horizon Therapeutics Plc | $11.04 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$11,557,985.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.